Drug Profile
Roflumilast - Jiangsu Chia-tai Tianqing Pharmaceutical
Latest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator Takeda
- Developer Chia Tai Tianqing Pharmaceutical Group
- Class Aminopyridines; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Benzamides; Chlorinated hydrocarbons; Cyclopropanes; Fluorinated hydrocarbons; Skin disorder therapies; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 15 Feb 2022 No development reported - Phase-II for Chronic obstructive pulmonary disease in China (PO)
- 20 May 2019 Chia Tai Tianqing Pharmaceutical Group terminates a phase II trial for Chronic obstructive pulmonary disease in China (PO) (NCT02671942)
- 01 Mar 2016 Phase-II clinical trials in Chronic obstructive pulmonary disease in China (PO) (NCT02671942)